G1SK34 Stock Price and Chart — BMFBOVESPA:G1SK34

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

On July 17, 2025, GSK's stock fell 4.73% to $36.47 after the FDA advisory committee rejected the benefit/risk profile of Blenrep combinations at the proposed dosage.

GSK's solid balance sheet enables potential mergers and acquisitions, including a possible buyout of Viking Therapeutics, a firm focused on obesity drugs, despite overvaluation risks.

On July 25, 2025, GSK plc bought back 16,677,357 shares, increasing treasury shares to 234,811,740, which now represent 5.75% of voting rights from a total of 4,080,572,540 shares.

Analyze the impact Analyze the impact

About GSK PLC ORD GBP0.3125

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Check out other big names from the same industry as G1SK34.